A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- 27 Oct 2017 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 08 Aug 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
- 30 Sep 2016 New trial record